No Access
INSIDE INDUSTRY
https://doi.org/10.1142/S021903031800037XCited by:0 (Source: Crossref)
Abstract
Drugs to watch 2018
First Pharmaceutical Regulation Graduate Certificate programme offered by Duke-NUS CoRE
Evonik intensifies research into regenerative medicine
SGInnovate completes investment in deep tech startup NDR Medical Technology
Australian biotech AdAlta makes improvements to lung fibrosis drug
AI and blockchain will counteract unsustainability of soaring drug prices
Availability of orphan medicines varies between European countries
Keywords:
- Food and Drug Administration
- Hemlibra
- Biktarvy
- Ozempic
- Erleada
- Shingrix
- Patisiranm
- Epidiolex
- Aimovig
- Lanadelumab
- Elagolix
- Steglatro
- Sublocade
- Duke-NUS CoRE
- Pharmaceutical Regulation Graduate Certificate
- Evonik
- regenerative medicine
- Tissue Engineering Project House
- SGInnovate
- NDR Medical Technology
- Artificial Intelligence
- AdAlta
- lung fibrosis drug
- Disruptive technologies
- personalized treatment
- drug prices
- orphan medicines
- European countries
- rare diseases
